Search clinical trials for: MEDI-528 1 mg/kg

Total 2129 results

MedImmune LLC

Completed

Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers

Asthma

United States
MedImmune LLC

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528

Healthy

United States
MedImmune LLC

Completed

A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma

Asthma

Canada
MedImmune LLC

Completed

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

Relapsed/Refractory Aggressive B-cell Lymphomas

United States
Aileron Therapeutics, Inc.

Completed

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

Growth Hormone Deficiency

United States
MedImmune LLC
AstraZeneca

Terminated

A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Mexico, Peru, South Africa, Canada
MedImmune LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children

Motavizumab Administration for a Second Season for RSV Prophylaxis

Chile, Brazil
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

Healthy Subjects

United States
MedImmune LLC

Completed

Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors

Cancer

France
AstraZeneca
MedImmune LLC

Terminated

Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee

Pain | Osteoarthritis

United Kingdom
Bio Sidus SA

Completed

PK/PD Study of 2 Agalsidase Formulations in Single Dose of 1 mg/kg Administered to Healthy Volunteers as IV Infusion

Fabry Disease

Argentina
Healthgen Biotechnology Corp.

Recruiting

Study of OsrhAAT or Placebo in Healthy Volunteers

Emphysema Secondary to Congenital AATD

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma

Asthma

United States, Canada
MedImmune LLC

Withdrawn

A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants

Wheezing
Pfizer

Completed

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Ludwig Institute for Cancer Research
Daiichi Sankyo Co., Ltd.; Austin Health

Completed

Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers (LUD2014-002)

Malignant Solid Tumor | Metastatic EphA2 Positive Cancer

Australia
AM-Pharma

Completed

Recombinant Human Alkaline Phosphatase in Healthy Japanese Subjects

Healthy

Japan
Pfizer

Completed

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, Canada, United States, Australia, United Kingdom, Belgium
Serum Institute of India Pvt. Ltd.
PPD

Completed

Safety Study of Dengushield in Healthy Adults

Dengue | Phase 1

Australia
Poitiers University Hospital

Completed

Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients

Morbid Obesity

France
Pfizer

Withdrawn

Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia

Dyslipidemia | Hypercholesterolemia
Corvus Pharmaceuticals, Inc.

Terminated

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

Covid-19

United States, Colombia, Spain, Canada, Peru, Brazil, Italy, Argentina, Chile, Germany, Mexico, Ukraine
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous
Alopexx Pharmaceuticals, LLC

Terminated

Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males

Neisseria Gonorrhoeae

United States
Programme National de Lutte contre l'Onchocercose...

Completed

Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients (EOLoa)

Onchocerciasis, Ocular | Loiasis

Congo
aTyr Pharma, Inc.

Completed

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

SARS-CoV-2 (COVID-19) Severe Pneumonia

United States, Puerto Rico
MedImmune LLC

Completed

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis, Relapsing Forms

United States, Spain, Poland, Ukraine
Alexion Pharmaceuticals

Completed

Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency | Cholesterol Ester Storage Disease(CESD) | LAL-Deficiency

France, United States, United Kingdom, Czechia
Flame Biosciences

Withdrawn

Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

Gastric Cancer | Solid Tumor | Pancreas Cancer
MedImmune LLC

Completed

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Respiratory Syncytial Virus Infections

United States, France, Spain, Denmark, Australia, New Zealand, Israel, United Kingdom, Italy, Sweden, Germany, Hungary, Chile, Argentina, Austria, Brazil, Bulgaria, Canada, Czech Republic, Greece, Iceland, Poland, Russian Federation, ...
Bristol-Myers Squibb

Completed

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Melanoma

France, Canada, United States, Germany, Australia, Russian Federation, Spain, Italy, Netherlands, Poland, Denmark, Israel, United Kingdom
MedImmune LLC

Completed

Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma

Malignant Melanoma

United States
MedImmune LLC

Completed

Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524

Respiratory Syncytial Virus Infections

Chile, Argentina
Janssen-Cilag International NV

Completed

A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers

Healthy

Belgium
MedImmune LLC

Completed

Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis

Psoriasis

United States, Canada
Cara Therapeutics, Inc.

Completed

Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery

Acute Pain

United States
Regeneron Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

Respiratory Syncytial Virus Infections

United States, Australia, Bulgaria, Canada, Chile, Denmark, Finland, Germany, Hungary, Netherlands, New Zealand, Panama, Puerto Rico, South Africa, Spain, Sweden, Turkey, Ukraine, United Kingdom
MedImmune LLC

Completed

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

RSV Illness in ≤12 Months of Participants

United States, Chile, New Zealand, Australia, Panama
MedImmune LLC

Completed

Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer

Cancer

United States
NoNO Inc.
University of Calgary

Completed

Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke (ESCAPE-NA1)

Stroke, Acute

United States, Ireland, Korea, Republic of, Canada, Sweden, Germany, United Kingdom, Australia
MedImmune LLC

Completed

MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States

Healthy

United States
MedImmune LLC

Terminated

A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness

Participants Less Than 12 Months of Age With RSV Illness

United States
MedImmune LLC

Completed

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma

United States, France, Spain, Canada, Turkey, Israel, Germany, Russian Federation, Czechia, Hungary, Poland
MedImmune LLC

Completed

Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection

Respiratory Syncytial Virus Prophylaxis
MedImmune LLC

Completed

Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults

Respiratory Syncytial Virus Infections

United States
Centocor, Inc.

Completed

A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Pulmonary Fibrosis

United States, Canada, Netherlands, Belgium, Germany
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
GlaxoSmithKline

Completed

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects (DEMAND I)

Muscular Dystrophies

France, United States
Gangnam Severance Hospital

Completed

Remimazolam Bolus for General Anesthesia

Loss of Consciousness

Korea, Republic of
Abbott

Completed

Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children

Premature Birth | Congenital Heart Disease | Bronchopulmonary Dysplasia | Respiratory Syncytial Virus Infection

Russian Federation

3

Subscribe